BioCentury | Aug 9, 2010
Company News

Tengion management update

...Genitourinary, Gene/Cell therapy, Transplant Hired: A. Brian Davis as CFO, formerly SVP and CFO of Neose Technologies Inc. WIR...
BioCentury | Jun 21, 2010
Company News

Neose hematology, biomanufacturing news

...a subsidiary of ratiopharm GmbH (Ulm, Germany) for $43 million (see BioCentury, March 9, 2009). Neose Technologies Inc....
BioCentury | Mar 9, 2009
Company News

Neose hematology, biomanufacturing news

...Neose completed its previously announced liquidation. In January, Neose estimated that it would distribute $19.5-$30 million...
...AG, a subsidiary of ratiopharm GmbH (Ulm, Germany) for $43 million (see BioCentury, Feb. 2). Neose Technologies Inc....
BioCentury | Feb 2, 2009
Company News

Neose, Novo Nordisk, ratiopharm deal

...of Neose's assets for $43 million. Neose plans to file for dissolution by March 2. Neose...
...in cash to its shareholders when the liquidation is complete (see BioCentury, Sept. 29, 2008). Neose Technologies Inc....
BioCentury | Sep 29, 2008
Company News

Neose, Novo Nordisk, ratiopharm deal

...subsidiary for a total of about $43 million in cash. Novo will acquire IP covering Neose's...
...acquire Neose's GlycoPEG-GCSF. Under a 2005 deal, BioGeneriX had an exclusive, worldwide license to use Neose's...
...The company had a 2007 operating loss of $36.9 million. RBC Capital Markets advised Neose. Neose Technologies Inc....
BioCentury | Jun 30, 2008
Clinical News

GlycoPEG-GCSF: Phase II started

...of subcutaneous GlycoPEG-GCSF vs. 6 mg Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Neose Technologies Inc....
BioCentury | May 26, 2008
Company News

Neose, Novo Nordisk deal

...received an undisclosed research milestone payment from Novo Nordisk under a 2003 deal to use Neose’s...
...to develop GlycoPEGylated versions of recombinant Factors VIIa and VIII (see BioCentury, Nov. 24, 2003). Neose Technologies Inc....
BioCentury | Apr 21, 2008
Clinical News

GlycoPEGylated Factor VIIa regulatory update

...and B, was developed using Neose's GlycoPEGylation technology. The product is in Phase I testing. Neose Technologies Inc....
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...the current study design in light of scientific data from recent intima-media thickness (IMT) studies" Neose...
BioCentury | Apr 7, 2008
Finance

Restructuring watch

...for new development projects after its ragweed allergy vaccine failed a Phase III trial 1/29/08 Neose...
Items per page:
1 - 10 of 172
BioCentury | Aug 9, 2010
Company News

Tengion management update

...Genitourinary, Gene/Cell therapy, Transplant Hired: A. Brian Davis as CFO, formerly SVP and CFO of Neose Technologies Inc. WIR...
BioCentury | Jun 21, 2010
Company News

Neose hematology, biomanufacturing news

...a subsidiary of ratiopharm GmbH (Ulm, Germany) for $43 million (see BioCentury, March 9, 2009). Neose Technologies Inc....
BioCentury | Mar 9, 2009
Company News

Neose hematology, biomanufacturing news

...Neose completed its previously announced liquidation. In January, Neose estimated that it would distribute $19.5-$30 million...
...AG, a subsidiary of ratiopharm GmbH (Ulm, Germany) for $43 million (see BioCentury, Feb. 2). Neose Technologies Inc....
BioCentury | Feb 2, 2009
Company News

Neose, Novo Nordisk, ratiopharm deal

...of Neose's assets for $43 million. Neose plans to file for dissolution by March 2. Neose...
...in cash to its shareholders when the liquidation is complete (see BioCentury, Sept. 29, 2008). Neose Technologies Inc....
BioCentury | Sep 29, 2008
Company News

Neose, Novo Nordisk, ratiopharm deal

...subsidiary for a total of about $43 million in cash. Novo will acquire IP covering Neose's...
...acquire Neose's GlycoPEG-GCSF. Under a 2005 deal, BioGeneriX had an exclusive, worldwide license to use Neose's...
...The company had a 2007 operating loss of $36.9 million. RBC Capital Markets advised Neose. Neose Technologies Inc....
BioCentury | Jun 30, 2008
Clinical News

GlycoPEG-GCSF: Phase II started

...of subcutaneous GlycoPEG-GCSF vs. 6 mg Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Neose Technologies Inc....
BioCentury | May 26, 2008
Company News

Neose, Novo Nordisk deal

...received an undisclosed research milestone payment from Novo Nordisk under a 2003 deal to use Neose’s...
...to develop GlycoPEGylated versions of recombinant Factors VIIa and VIII (see BioCentury, Nov. 24, 2003). Neose Technologies Inc....
BioCentury | Apr 21, 2008
Clinical News

GlycoPEGylated Factor VIIa regulatory update

...and B, was developed using Neose's GlycoPEGylation technology. The product is in Phase I testing. Neose Technologies Inc....
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...the current study design in light of scientific data from recent intima-media thickness (IMT) studies" Neose...
BioCentury | Apr 7, 2008
Finance

Restructuring watch

...for new development projects after its ragweed allergy vaccine failed a Phase III trial 1/29/08 Neose...
Items per page:
1 - 10 of 172